Sunday, December 10, 2017 10:01:24 AM
The plaintiff claims that the IPO Registration Statement and Prospectus materially and falsely failed to disclose that Avinger lacked adequate personnel to increase sales of its lumivascular-platform products and to commercialize Pantheris, that Avinger experienced problems with the robustness of its lumivascular-platform devices (including Pantheris), that physicians and hospitals were requiring more extensive training concerning Avinger’s products as compared to competing products, that Avinger would not be able to rapidly ramp up sales of its lumivascular platform, and that as a result, Avinger experienced lower than expected sales and revenues.
Those who purchased Avinger Inc (NASDAQ:AVGR) shares should contact the Shareholders Foundation, Inc.
A buyout in the making perhaps?
Recent AVGR News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/08/2024 09:31:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:13 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:41:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:21:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 09:17:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:11:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 10:11:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 09:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 10:02:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:30:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/01/2023 09:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 01:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:32:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/22/2023 09:32:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 09:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:35:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 08:09:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 10:06:54 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/22/2023 10:03:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/21/2023 10:05:05 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/21/2023 10:02:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 10:05:22 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/20/2023 10:02:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:56:15 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM